News & Insights
June 11, 2026 | For Immediate Release
Cell Envision’s Sign-Series Liquid Biopsy Analysis Addresses the Next Frontier of Multi-Cancer Early Detection with Cellular Immune Profiling
Responding to key trends from ASCO 2026: delivering tumor immune microenvironment intelligence through Sign-Series Liquid Biopsy Analysis to complement the evolving precision oncology paradigm
In May 2026, the world’s largest randomized controlled trial of a multi-cancer early detection (MCED) test presented its full results at the American Society of Clinical Oncology Annual Meeting (ASCO 2026) in Chicago — marking a pivotal transition for liquid biopsy from proof-of-concept into clinical integration. Cell Envision believes this milestone opens an important space for cell-based immune phenotyping as a complementary and differentiated approach within the next generation of MCED.
ASCO 2026: The Era of Precision Biomarkers Has Arrived
This year’s ASCO Annual Meeting, themed “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide,” brought together more than 35,000 oncology professionals around a single converging theme: how to use more precise biomarkers, at the right moment, to select the most appropriate treatment for each individual patient.
Several landmark data readouts at the meeting — including a near-doubling of median overall survival in pancreatic cancer with RAS-targeted therapy, a new first-line standard in lung cancer with a PD-1/VEGF bispecific antibody, and dual survival endpoints achieved by a next-generation antibody-drug conjugate in triple-negative breast cancer (TNBC) — collectively signal a structural shift: single-analyte biomarkers are no longer sufficient to support modern precision oncology decision-making, and multi-dimensional integrated analysis has become clinical consensus.
“Biomarkers, biomarkers, biomarkers — not only in lung cancer but in all cancers — have become critical in allowing us to select the best therapy for the patient in front of us in clinic.”
— Thoracic oncology expert perspective, ASCO 2026
The Next Step in Multi-Cancer Early Detection: Integrating Cellular Immune Information
ASCO 2026 also saw the presentation of full results from the largest MCED randomized controlled trial conducted to date. Three years of annual screening demonstrated a meaningful reduction in late-stage cancer diagnoses and a four-fold increase in screen-detected cancers compared with standard care alone — a promising directional signal for the future of cancer screening.
Against this backdrop, the scientific and clinical communities have simultaneously called for the development of multimodal liquid biopsy — extending beyond cell-free DNA (cfDNA) analysis to integrate the phenotypic profiles of circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs), alongside tumor immune microenvironment data, in order to build a more complete oncological assessment framework.
The Sign-Series: Tumor Immune Microenvironment Intelligence at the Cellular Level
Cell Envision’s proprietary CytoSCM™ all-in-one platform uses peripheral blood as its sole specimen source and applies multi-fluorescence staining to perform cell-level analysis of circulating tumor microemboli (CTMs — clusters of tumor cells circulating in the bloodstream with high metastatic potential) and disseminated tumor cells (DTCs — individual tumor cells that have detached from the primary tumor and entered systemic circulation). Unlike approaches that analyze fragmented cell-free DNA, the Sign-Series directly characterizes the surface markers of intact tumor cells alongside the surrounding immune cell composition, generating clinical information across the following dimensions:
- Sign-I — Anti-Tumor Immunity Assessment: Detects the presence of CTMs and DTCs, quantifies the CD4/CD8 immune cell ratio, and evaluates the host’s anti-tumor immune surveillance capacity. A single blood draw enables multi-cancer screening across 14 or more cancer types.
- Sign-II — CTM Tumor Immune Microenvironment Profiling: Analyzes tumor-infiltrating lymphocytes (TIL-T; CD8/CD103), immunosuppressive cells (MDSCs and Tregs), NK cells, and dynamic PD-L1 expression surrounding CTMs — assessing whether the tumor immune landscape is in an activated or suppressed state.
- T-cell to Circulating Tumor Cell (T/CTC) Ratio: Serves as both a prognostic biomarker and a predictive biomarker for treatment response, providing an objective basis for patient selection in immune cell therapy.
- Longitudinal Dynamic Monitoring: Repeat testing every 3 to 6 months enables tracking of changes in CTM immune microenvironment composition over time, offering an evidence-based reference for adjusting treatment strategy.
An Integrated Platform: From Liquid Biopsy to Cell Therapy — a Complete Clinical Loop
Cell Envision’s core technological advantage lies in the fact that the Sign-Series is not solely a diagnostic tool — it is the patient assessment gateway to CytoTIL™, our autologous selective memory T-cell therapy manufactured from peripheral blood. Once Sign-II confirms the presence of immunologically active TIL-like cells in a patient’s blood, Sign-III (ex vivo Blood-T Culture Assay) can be used for further validation, seamlessly connecting to the CytoTIL™ manufacturing workflow. This creates a fully integrated clinical path from detection → immune assessment → cell therapy — realized through a simple blood draw, without the need for invasive tumor biopsies.
“Our goal is to give every patient who undergoes Sign testing a clear picture of how their immune system is interacting with their tumor — not just whether a tumor signal exists, but whether the immune system is gaining ground or being suppressed. That is the information precision oncology actually needs.”
— Cell Envision Research & Development Team
Strategic Direction: Positioning the Sign-Series Within the ASCO 2026 Landscape
In response to the precision medicine trends highlighted at ASCO 2026, Cell Envision will continue to advance the following strategic priorities:
- Actively expanding clinical data collection for Sign-I and Sign-II longitudinal monitoring to support alignment with evolving ASCO treatment guidelines.
- Advancing the IND filing for CytoTIL™ in lung cancer, establishing Sign-III as a formal cellular therapy eligibility and monitoring tool.
- Expanding the Asia-Pacific network of partner healthcare institutions to build a standardized Sign-Series → CytoTIL™ clinical workflow under applicable cell therapy regulatory frameworks.
About Cell Envision Inc.
Cell Envision Inc. (賽爾奈微生醫股份有限公司) is a precision medicine company specializing in rare circulating cell technology. The company’s proprietary CytoSCM™ all-in-one liquid biopsy platform powers the Sign-Series of CTM/DTC immune cell pathology analyses, and underpins the development of CytoTIL™ — an autologous selective memory T-cell therapy manufactured from peripheral blood — in pursuit of its mission to transform cancer into a manageable chronic condition. Cell Envision holds 9 patents across the United States, Taiwan, and PCT international filings, and achieved ISO 17025 laboratory accreditation in 2022.
Website: www.cellenvision.com | www.cellenvision.com.tw
Media Contact
Cell Envision Inc.
Email: [email protected]
Website: www.cellenvision.com
© 2026 Cell Envision Inc. All rights reserved. This press release is provided for informational purposes only and does not constitute medical advice. Information current as of June 11, 2026.
informational purposes only and does not constitute medical advice. Information current as of June 11, 2026.